Related Experiment Videos
Peritoneal ultrafiltration and refractory congestive heart failure
J P Ryckelynck1, T Lobbedez, B Valette
1Division of Nephrology, Dialysis, Renal Transplantation, Clemenceau University Hospital, Caen, France.
Summary
Peritoneal ultrafiltration (PUF) improved clinical conditions for patients with drug-refractory congestive heart failure (CHF). This treatment led to significant weight loss and reduced hospitalization, enhancing quality of life.
Area of Science:
- Cardiology
- Nephrology
- Internal Medicine
Background:
- Congestive heart failure (CHF) refractory to maximal drug therapy presents significant challenges.
- Resistant congestive heart failure (RCHF) often leads to increased morbidity and reduced quality of life.
- Alternative management strategies are needed for patients with RCHF.
Purpose of the Study:
- To evaluate the efficacy of peritoneal ultrafiltration (PUF) in improving clinical conditions for patients with RCHF.
- To assess the morbidity associated with RCHF and PUF.
- To determine the impact of PUF on hospitalization rates and quality of life.
Main Methods:
- Prospective, nonrandomized study of 16 patients with NYHA class III/IV CHF refractory to maximal medical therapy.
- Peritoneal ultrafiltration (PUF) administered using a 2-L hypertonic dialysis solution, daily or every other day.
- Clinical parameters, weight, sodium removal, and hospitalization data were monitored.
Main Results:
- All patients experienced clinical improvement with significant weight reduction (mean 5.5 kg).
- Average weekly ultrafiltration was 3.74 L, with effective sodium removal.
- Mean hospitalization time decreased from 4.4 to 1.20 days per patient per year post-PUF.
Conclusions:
- Peritoneal ultrafiltration (PUF) is an effective treatment for improving functional status and quality of life in patients with RCHF.
- PUF demonstrated a low rate of hospitalization, suggesting a favorable risk-benefit profile.
- Further research may explore PUF as a viable option for selected RCHF patients.